HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GNC ID Policy Aimed At Halting Minors’ Purchases Of Ephedra

This article was originally published in The Tan Sheet

Executive Summary

GNC will institute a nationwide identification policy in early 2003 for purchasers of products intended for use only by individuals over age 18, the Royal Numico division announced Nov. 6

You may also be interested in...



GNC carding policy

ID policy regarding products intended for adult users will encompass DHEA, kava, melatonin, synephrine, vincamine supplements, as well as ephedra, andro, GNC parent Royal Numico says. Also, GNC will "share best practices and recommendations with our vendors" following retailer's review of its own labeling practices to ensure labels provide clear information. GNC announced the initiatives Nov. 6 (1"The Tan Sheet" Nov. 11, 2002, p. 4)...

GNC On The Line: Retailer Faces “Probation” Period To Shape Up Financials

Royal Numico is giving subsidiary GNC a 12- to 18-month probationary period to ramp up its financial performance, President & CEO Jan Bennink told analysts in London Nov. 8

CRN Sports Supplement Guidelines Use “Green Light, Red Light” Model

Guidelines on the use of sports nutrition supplements by young athletes will be posted on the 1Council for Responsible Nutrition's Web site the week of Oct. 21

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel